J Korean Cancer Assoc.
2000 Feb;32(1):148-155.
Stereotactic Radiotherapy for the Treatment of Brain Metastases
- Affiliations
-
- 1Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 2Departments ofNeurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
-
PURPOSE: To evaluate the clinical results of stereotactic
radiosurgery (SRS) and frac- tionated stereotactic radiotherapy
(FSRT) for metastatic brain tumors.
MATERIALS AND METHODS
Nineteen patients with brain metastases
(34 lesions) were treated with LINAC-based SRS or FSRT with or without
whole brain radiotherapy between October 1995 and February 1998. SRS
was preferred to FSRT in cases with three or more lesions and poor
performance status. FSRT was preferred to SRS in cases with lesions
larger than 3 cm and lesions located near or at the eloquent areas
such as thalamus, brain stem, and optic apparatus. Single isocenter
was used both in SRS and FSRT, and the median peripheral dose in SRS
was 15 Gy (range 13~20 Gy), while that in FSRT was 21 Gy (range 15~24 Gy)
by 3 Gy per fraction.
RESULTS
Local control was achieved in 79% (27/34 treated lesions)
and 1-year over- all survival rate was 58% with the median survival
of 12 months. Lethal progressive brain metastases, both local and
regional, were in four patients (27% of all deaths). No significant
differences in local control and survival was observed with histology,
age, sex, performance status, tumor volume, number of lesions, or
treatment modality. Unacceptable acute or late complications did not occur.
CONCLUSION
Stereotactic radiotherapy including SRS and FSRT is effective,
non-invasive therapy for brain metastases. This study suggests that stereotactic
radiotherapy might be an alternative to surgical resection in selected
patients of brain metastases.